VLPCOV-02
COVID-19 (booster)
Phase 1/2Active
Key Facts
About VLP Therapeutics
VLP Therapeutics is a clinical-stage biotech advancing a novel vaccine platform centered on self-amplifying RNA (saRNA) with modified nucleosides, such as 5-methylcytidine, to improve safety and immunogenicity. The company has a diversified pipeline including COVID-19, malaria, and dengue vaccines, as well as cancer immunotherapies, supported by partnerships and non-dilutive funding from entities like the Gates Foundation. With operations in the US and Japan, VLPT is positioning itself as a player in the next wave of mRNA and replicon vaccine technology, aiming for broader and more durable immune responses.
View full company profileTherapeutic Areas
Other COVID-19 (booster) Drugs
| Drug | Company | Phase |
|---|---|---|
| StealthX™ Vaccine | Capricor Therapeutics | Phase 1 |